1. ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin’s Disease
by J. Rodriguez, M.A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A. Sarris, J. Romaguera, B. Andersson, F. Cabanillas, and F.B. Hagemeister
Blood
Volume 93(11):
June 1, 1999
©1999 by American Society of Hematology

2. J. Rodriguez et al. Blood 1999;93:3632-3636
©1999 by American Society of Hematology

3. J. Rodriguez et al. Blood 1999;93:3632-3636
©1999 by American Society of Hematology

4. Overall survival according to response to ASHAP
Overall survival according to response to ASHAP. All patients underwent ABMT after ASHAP with the exception of 2 patients who received polyclonal antiferritin antibodies, and 3 had other chemotherapy salvage regimens.
Overall survival according to response to ASHAP. All patients underwent ABMT after ASHAP with the exception of 2 patients who received polyclonal antiferritin antibodies, and 3 had other chemotherapy salvage regimens.
J. Rodriguez et al. Blood 1999;93:
©1999 by American Society of Hematology

5. Overall survival of 41 patients who had both pre- and post-ASHAP gallium.
Overall survival of 41 patients who had both pre- and post-ASHAP gallium. According to gallium response, 23 became gallium negative (19 clinical CR + 4 clinical PR) whereas 18 remained gallium positive (16 clinical PR + 2 minor responses).
J. Rodriguez et al. Blood 1999;93:
©1999 by American Society of Hematology